abrdn Life Sciences Investors Q1 2026 Commentary
The Abrdn Life Sciences Investors Fund experienced a rise in its equity portion but did not meet the performance of its benchmark, the NASDAQ Biotechnology Index. The quarter saw U.S. equities initially resilient before a significant decline. Additionally, geopolitical tensions in the Middle East impacted oil shipments and airspace operations.
- ▪The equity portion of the Abrdn Life Sciences Investors Fund rose gross of fees.
- ▪The fund underperformed its benchmark, the NASDAQ Biotechnology Index.
- ▪U.S. equities ended the quarter sharply lower after being relatively resilient earlier.
- ▪The conflict in the Middle East led to airspace closures and oil shipment blockages.
- ▪The US Federal Reserve maintained the federal funds target range at 3.50%–3.75%.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":{"id":"DoxFkP"},"item":"https://seekingalpha.com/latest-articles"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4907081-abrdn-life-sciences-investors-q1-2026-commentary"},"author":{"@type":"Person","name":"Aberdeen Asset Management","url":"https://seekingalpha.com/author/aberdeen-asset-management"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
